Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Topamax approved for migraine prevention

Executive Summary

Ortho-McNeil's anti-convulsant Topamax (topiramate) clears FDA Aug. 11 for supplemental indication of prophylaxis of migraine headaches in adults. The recommended daily dose for migraines is 100 mg administered in two divided doses. Topamax' twice-daily migraine prevention regimen may place the drug at a disadvantage to Abbott's Depakote ER (divalproex extended-release), which has once-daily dosing . Ortho-McNeil received an "approvable" letter for the migraine indication in October 2003 (1"The Pink Sheet" Nov. 24, 2003, In Brief)...

You may also be interested in...

J&J Topamax “approvable” for migraines

Johnson & Johnson plans to respond around year-end to an Oct. 23 "approvable" letter for Topamax (topiramate) for the supplemental indication of prophylaxis of migraine headache. Final approval awaits additional analysis of safety data and labeling negotiations...

Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals

Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.

Rapid Biopharma Response To COVID-19 Enabled By Decades Of R&D Investment, Firms Say

Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts